上海阿拉丁生化科技股份有限公司
上海市上海市浦东新区
产品名：可的松
纯度：97.0%
规格：5g/1g/25g/1ml
联系人：阿拉丁

2881459338 复制
联系电话：400-620-6333

苏州市森菲达化工有限公司
江苏省苏州市相城区
产品名：可的松
纯度：98.0%
规格：200kg
联系人：程经理

3912721726 复制

18796480002 复制
联系电话：18796480002

查看所有供应商和价格请点击：

53-06-5生产厂家

53-06-5价格

53-06-5

53-06-5结构式

常用中文名：可的松
常用英文名：Cortisone
CAS号：53-06-5
分子式：C₂₁H₂₈O₅
分子量：360.444
相关类别：医药中间体杂环化合物嘧啶类化合物硝基嘧啶
发布时间：2018-06-21 18:17:51
更新时间：2026-07-01 12:23:54
Cortisone是一种用于治疗感染或过敏的激素药物

化源商城直购

中文名	可的松
英文名	cortisone
中文别名	2H8]-可的松(主要) (8S,9S,10R,13S,14S,17R)-17-羟基-17-(2-羟基乙酰基)-10,13-二甲基-1,2,6,7,8,9,12,14,15,16-十氢环戊烷并[A]菲-3,11-二酮 17-羟-11-脱皮质(甾)酮皮质酮/可的松 20-三酮甲醇中可的松泼尼松杂质A 甲醇中可的松-13C3同位素可的松Cortisone 可體松氢化可松杂质B (8S,9S,10R,13S,14S,17R)-17-羟基-17-(2-羟基乙酰)-10,13-二甲基-1,2,6,7 17α,21-二羟基孕甾-4-烯-3,11,20-三酮可的松 (溶液) 可的松-D2 醋酸波尼松杂质2 醋酸泼尼松杂质2 可的松(标准品) 可的松 100UG/ML溶于甲醇肾上腺皮质激素 17-羟-11脱氢皮质(甾)酮 11-去氢-17-羟基皮质酮,11-DEHYDRO-17-HYDROXYCORTICOSTERONE 皮質酮甲醇中可的松-[13C3] CORTISONE(标准品) 17Α,21-二羥-4-孕烯-3,11,20-三酮皮质酮(2,2,4,6,6,9,12,12-D8,) 甲醇中可的松-D2同位素肾上腺皮质激素、11-去氢-17-羟基皮质酮可的松(CTS) 21-二羟基孕甾-4-烯-3 皮质酮(2,3,C3,)100 UG / ML甲醇 11-去氫-17-羥皮質甾酮 11-去氢-17-羟基皮质酮可的松检测标准品 11-脱氢-17-羟皮质酮 11-去氢-17-羟皮质甾酮 (8S,9S,10R,13S,14S,17R)-17-羟基-17-(2-羟基-1-氧代乙基)-10,13-二甲基-1,2,6,7,8,9,12,14,15,16-十氢环戊烷并[A]菲-3,11-二酮氢化可的松杂质B 可的松(2,2,4,6,6,9,12,12-D8, ) 乙腈中可的松 17-羟-11脱氢皮质酮可的松溶液, 100PPM 可的松/氢化可的松杂质B 标准品甲醇中可的松溶液标准物质 17Α,21-二羟基-4-孕甾烯-2,11,20-三酮,17Α,21-DIHYDROXY-4-PREGNENE-3,11,20-TRIONE 17Α,21-二羟基孕甾-4-烯-3,11,20-三酮甲醇中可的松标准溶液 17-羟-11-脱皮质酮
英文别名	Cortadren Reichstein's substance FA REICHSTEIN'S SUBSTANCE 'FA' (8S,9S,10R,13S,14S,17R)-17-glycoloyl-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-quinone Cortison [3H]-Cortisone EINECS 200-162-4 17ALPHA,21-DIHYDROXYPREGN-4-ENE-3,11,20-TRIONE 4-PREGNEN-17ALPHA,21-DIOL-3,11,20-TRIONE delta(sup4)-pregnene-17alpha,21-diol-3,11,20-trione 17A 21-DIHYDROXY-4-PREGNEN-3 17 20-TRIONE (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-diMethyl-7,8,9,10,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11(2H,6H)-dione Adreson Kendall's compound E 11-DEHYDRO-17-HYDROXYCORTICOSTERONE 17α,21-Dihydroxypregn-4-ene-3,11,20-trione MFCD00003610 Cortisate Andreson Kendall's compound Hydrocortisone Impurity B Cortisone solution KENDALL'S COMPOUND 'E' 17ALPHA-HYDROXY-11-DEHYDROCORTICOSTERONE Cortistal 4-Pregnene-17α,21-diol-3,11,20-trione 4-PREGNENE-17ALPHA,21-DIOL-3,11,20-TRIONE (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyethanoyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione D4-Pregnene-17a,21-diol-3,11,20-trione Cortogen Reichstein Fa 4-PREGEN-17A,21-DIOL-3,11,20-TRIONE 4-Pregnen-17a,21-diol-3,11,20-trione-d2 Cortisone solution,100ppm Incortin Cortivite KENDALL'S CMPD ''E'' 20-trione,17,21-dihydroxy-pregn-4-ene-11 DELTA-PREGNENE-17ALPHA,21-DIOL-3,11,20-TRIONE KENDALL'S ''E'' (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione Scheroson CORTISONE REICHSTEIN'S COMPOUND ''FA'' Corlin 17,21-Dihydroxy-4-pregnene-3,11,20-trione (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyethanoyl)-10,13-dimethyl-1,2,6,7,8,9,12 17a,21-Dihydroxy-4-pregnene-3,11,20-trione Pregn-4-ene-3,11,20-trione, 17,21-dihydroxy 17-HYDROXY-11-DEHYDROCORTICOSTERONE CORTONE DELTA4-PREGNENE-17ALPHA,21-DIOL-3,11,20-TRIONE 17ALPHA,21-DIHYDROXY-4-PREGNENE-3,11,20-TRIONE KENDALL'S COMPOUND E Adrenalex 17,21-Dihydroxypregn-4-ene-3,11,20-trione Pregn-4-en-17alpha,21-diol-3,11,20-trione REICHSTEIN'S SUBSTANCE FA Cortone Cortandren 4-PREGNEN-17,21-DIOL-3,11,20-TRIONE (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxy-1-oxoethyl)-10,13-dimethyl-1,2,6,7,8,9,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,11-dione DELTA4-PREGNENE-17, 21-DIOL-3, 11, 20-TRIONE Cortisone-[2H7] Cortisal

描述	Cortisone是一种用于治疗感染或过敏的激素药物
相关类别	信号通路 >> G 蛋白偶联受体/G 蛋白 >> 糖皮质激素受体研究领域 >> 炎症/免疫

密度	1.3±0.1 g/cm3
沸点	567.8±50.0 °C at 760 mmHg
熔点	223-228 °C (dec.)(lit.)
分子式	C₂₁H₂₈O₅
分子量	360.444
闪点	311.2±26.6 °C
精确质量	360.193665
PSA	91.67000
LogP	1.44
外观性状	白色粉末
蒸汽压	0.0±3.5 mmHg at 25°C
折射率	1.587
储存条件	本品应密封于阴凉干燥处保存。
稳定性	常温常压下性质稳定
分子结构	1、摩尔折射率：94.17 2、摩尔体积（cm³/mol）：280.3 3、等张比容(90.2K)：769.4 4、表面张力(dyne/cm)：56.7 5、极化率(10-24cm³)：37.33
计算化学	1、疏水参数计算参考值（XlogP）：1.5 2、氢键供体数量：2 3、氢键受体数量：5 4、可旋转化学键数量：2 5、互变异构体数量：45 6、拓扑分子极性表面积（TPSA）：91.7 7、重原子数量：26 8、表面电荷：0 9、复杂度：724 10、同位素原子数量：0 11、确定原子立构中心数量：6 12、不确定原子立构中心数量：0 13、确定化学键立构中心数量：0 14、不确定化学键立构中心数量：0 15、共价键单元数量：1
更多	1. 性状：白色结晶性粉末。系肾上腺的分泌物。 2. 密度（g/mL,25/4℃）：未确定 3. 相对蒸汽密度（g/mL,空气=1）：未确定 4. 熔点（ºC）： 220～224℃（部分分解）。 5. 沸点（ºC,常压）：未确定 6. 沸点（ºC,5.2kPa）：未确定 7. 折射率：未确定 8. 闪点（ºC）：未确定 9. 比旋光度（º）：[α]D25 +209°（C=1.2，95%乙醇中），[α]54625 +269°（C=0.125，苯中） 10. 自燃点或引燃温度（ºC）：未确定 11. 蒸气压（kPa,25ºC）：未确定 12. 饱和蒸气压（kPa,60ºC）：未确定 13. 燃烧热（KJ/mol）：未确定 14. 临界温度（ºC）：未确定 15. 临界压力（KPa）：未确定 16. 油水（辛醇/水）分配系数的对数值：未确定 17. 爆炸上限（%,V/V）：未确定 18. 爆炸下限（%,V/V）：未确定 19. 溶解性：溶于乙醇、丙酮、和冷甲醇，极少溶于乙醚、苯和氯仿，微溶于水（25℃，28mg/100ml），水溶液呈中性。在浓硫酸中呈深红色溶液，并有深绿色荧光。加热能还原本尼迪特（Benedict’s）溶液。

可的松 修改号码：5

模块1. 化学品
产品名称： Cortisone
修改号码： 5

模块2. 危险性概述
GHS分类

　物理性危害未分类
　健康危害未分类
　环境危害未分类
GHS标签元素
　图标或危害标志无
　信号词无信号词
　危险描述无
　防范说明无

模块3. 成分/组成信息
单一物质/混和物单一物质
化学名(中文名)：可的松
百分比： >97.0%(LC)
CAS编码： 53-06-5
俗名： 17α,21-Dihydroxypregn-4-ene-3,11,20-trione
分子式： C21H28O5

模块4. 急救措施
吸入： 将受害者移到新鲜空气处，保持呼吸通畅，休息。若感不适请求医/就诊。
皮肤接触： 立即去除/脱掉所有被污染的衣物。用水清洗皮肤/淋浴。
若皮肤刺激或发生皮疹：求医/就诊。
眼睛接触：用水小心清洗几分钟。如果方便，易操作，摘除隐形眼镜。继续清洗。
如果眼睛刺激：求医/就诊。
食入： 若感不适，求医/就诊。漱口。
紧急救助者的防护：救援者需要穿戴个人防护用品，比如橡胶手套和气密性护目镜。

模块5. 消防措施
合适的灭火剂：干粉，泡沫，雾状水，二氧化碳
可的松 修改号码：5

模块5. 消防措施
特定方法：从上风处灭火，根据周围环境选择合适的灭火方法。
非相关人员应该撤离至安全地方。
周围一旦着火：如果安全，移去可移动容器。
消防员的特殊防护用具：灭火时，一定要穿戴个人防护用品。

模块6. 泄漏应急处理
个人防护措施，防护用具， 使用个人防护用品。远离溢出物/泄露处并处在上风处。
紧急措施：泄露区应该用安全带等圈起来，控制非相关人员进入。
环保措施：防止进入下水道。
控制和清洗的方法和材料：清扫收集粉尘，封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的
法律法规处置。

模块7. 操作处置与储存
处理
技术措施：在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手
和脸。
注意事项：如果粉尘或浮质产生，使用局部排气。
操作处置注意事项：避免接触皮肤、眼睛和衣物。
贮存
储存条件：保持容器密闭。存放于凉爽、阴暗处。
远离不相容的材料比如氧化剂存放。
包装材料：依据法律。

模块8. 接触控制和个体防护
工程控制：尽可能安装封闭体系或局部排风系统，操作人员切勿直接接触。同时安装淋浴器和洗
眼器。
个人防护用品
　呼吸系统防护：防尘面具。依据当地和政府法规。
　手部防护：防护手套。
　眼睛防护：安全防护镜。如果情况需要，佩戴面具。
　皮肤和身体防护：防护服。如果情况需要，穿戴防护靴。

模块9. 理化特性
固体
外形（20°C）：
外观： 晶体-粉末
颜色： 白色-极淡的黄色
气味：无资料
pH:无数据资料
熔点：无资料
沸点/沸程无资料
闪点：无资料
爆炸特性
　爆炸下限：无资料
　爆炸上限：无资料
密度：无资料
溶解度：
[水]无资料
[其他溶剂]无资料
可的松 修改号码：5

模块10. 稳定性和反应性
化学稳定性：一般情况下稳定。
危险反应的可能性：未报道特殊反应性。
须避免接触的物质氧化剂
危险的分解产物: 一氧化碳, 二氧化碳

模块11. 毒理学信息
急性毒性：无资料
对皮肤腐蚀或刺激：无资料
对眼睛严重损害或刺激：无资料
生殖细胞变异原性：无资料
致癌性：
IARC =无资料
NTP =无资料
生殖毒性：无资料
RTECS 号码: GM9020000

模块12. 生态学信息
生态毒性：
鱼类：无资料
甲壳类：无资料
藻类：无资料
残留性 / 降解性：无资料
潜在生物累积（BCF):无资料
土壤中移动性
　log水分配系数：无资料
　土壤吸收系数（Koc）：无资料
　亨利定律无资料
constant(PaM3/mol):

模块13. 废弃处置
如果可能，回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合，在装有后燃和洗涤装置的化学焚烧炉中
焚烧。废弃处置时请遵守国家、地区和当地的所有法规。

模块14. 运输信息
联合国分类：与联合国分类标准不一致
UN编号：未列明

模块15. 法规信息
《危险化学品安全管理条例》（2002年1月26日国务院发布，2011年2月16日修订）: 针对危险化学品的安全使用、
生产、储存、运输、装卸等方面均作了相应的规定。
可的松 修改号码：5

模块16 - 其他信息
N/A

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GM9020000

CHEMICAL NAME :: Cortisone

CAS REGISTRY NUMBER :: 53-06-5

LAST UPDATED :: 199707

DATA ITEMS CITED :: 32

MOLECULAR FORMULA :: C21-H28-O5

MOLECULAR WEIGHT :: 360.49

WISWESSER LINE NOTATION :: L E5 B666 CV OV MUTJ A1 E1 FV1Q FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 90 mg/kg

SEX/DURATION :: female 90 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 160 mg/kg

SEX/DURATION :: female 16 week(s) pre-mating female 1-39 week(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - other neonatal measures or effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 476 mg/kg

SEX/DURATION :: female 1-34 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 500 mg/kg

SEX/DURATION :: female 8-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 110 mg/kg

SEX/DURATION :: female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - delayed effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 225 mg/kg

SEX/DURATION :: female 13-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 110 mg/kg

SEX/DURATION :: female 1-22 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - endocrine system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 82500 ug/kg

SEX/DURATION :: female 11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 35 mg/kg

SEX/DURATION :: female 7 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 144 mg/kg

SEX/DURATION :: male 9 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1 gm/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 400 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 200 mg/kg

SEX/DURATION :: female 11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 400 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 400 mg/kg

SEX/DURATION :: female 11-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 100 mg/kg

SEX/DURATION :: female 11-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 300 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 300 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 120 mg/kg

SEX/DURATION :: female 1 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Fertility - other measures of fertility

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Parenteral

DOSE :: 32 mg/kg

SEX/DURATION :: female 20-27 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 450 mg/kg

SEX/DURATION :: female 16-30 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: Cytogenetic analysis

TYPE OF TEST :: Unscheduled DNA synthesis

TYPE OF TEST :: DNA inhibition

MUTATION DATA

TYPE OF TEST :: DNA damage

TEST SYSTEM :: Mammal - species unspecified Lymphocyte

DOSE/DURATION :: 10 umol/L

REFERENCE :: ENZYAS Enzymologia. (The Hague, Netherlands) V.1-43, 1936-72. Volume(issue)/page/year: 41,183,1971 *** REVIEWS *** TOXICOLOGY REVIEW AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 96,985,1966 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,1045,1956 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3836 No. of Facilities: 27 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 936 (estimated) No. of Female Employees: 906 (estimated)

符号	GHS08
信号词	Warning
危害声明	H361d
警示性声明	P281
个人防护装备	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
危害码 (欧洲)	F,T,Xn
风险声明 (欧洲)	11-23/24/25-39/23/24/25-63
安全声明 (欧洲)	S22-S24/25
危险品运输编码	NONH for all modes of transport
WGK德国	3
RTECS号	GM9020000
海关编码	2937210000

上游产品 4
50-04-4 3597-44-2 3941-62-6 128802-52-8
下游产品 10
382-45-6 3615-87-0 3597-46-4 53-36-1
50-23-7 516-15-4 72-23-1 1882-82-2
83-43-2 739-27-5